Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

EPRX stock hub

Eupraxia Pharmaceuticals Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

EPRXis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

463.2M

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

EPRX

In the news

Latest news · EPRX

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-68.8

P25 -105.6P50 -46.5P75 -3.1

ROIC-42.7

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All EPRX market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

168

Groups with data

Currency

USD

Showing 168 of 168 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001581178
Company name	Eupraxia Pharmaceuticals Inc.
Country	Canada
Country code	US
Employees	49
Employees Change	16%
Employees Change Percent	48.48
Enterprise value	$410.9M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
Isin	CA29842P1053
Last refreshed	2026-05-10
Market cap	$463.2M
Market cap category	Small-Cap
Price	$7.45
Price currency	USD
Sector	Healthcare
Sic	2834
Symbol	EPRX
Website	https://www.eupraxiapharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-8.87%
FCF yield	-6.29%
P/B ratio	5.76x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Net Income	$-41.1M
Net Income Growth Years	0%
Profit Per Employee	$-838,918
ROA	-39.67
Roa5y	-61.98
ROCE	-47.73
ROE	-68.76
ROIC	-42.7

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	96.92%
Cagr3y	19.64%
EPS Growth Years	0
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$86.2M
Cash	$80.6M
Current Assets	$85.1M
Current Liabilities	$5.6M
Debt	$154,362
Debt Equity	$0
Equity	$80.4M
Liabilities	$5.7M
Long Term Assets	$1.1M
Long Term Liabilities	$75,910
Net Cash	$80.4M
Net Cash By Market Cap	$17.36
Net Cash Growth	143.45%
Net Debt Equity	$-1
Tangible Book Value	$52.3M
Tangible Book Value Per Share	$1.01
WACC	12.03

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	15.12
Net Working Capital	$-1M
Quick ratio	14.43
Working Capital	$79.5M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-17.76%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	96.83%
200-day SMA	6.71
3Y total return	71.26%
50-day SMA	7.37
50-day SMA vs 200-day SMA	50over200
All Time High	9.32
All Time High Change	-20.06%
All Time High Date	2026-01-21
All Time Low	0.85
All Time Low Change	776.37%
All Time Low Date	2022-06-27
ATR	0.43
Beta	1.42
Ch YTD	-1.32
High	7.6
High52	9.32
High52 Date	2026-01-21
High52ch	-20.06%
Low	7.25
Low52	3.67
Low52 Date	2025-05-14
Low52ch	103.16%
Ma50ch	1.11%
Price vs 200-day SMA	10.96%
RSI	52.05
RSI Monthly	63.2
RSI Weekly	53.82
Sharpe ratio	1.35x
Sortino ratio	2.48
Total Return	-17.76%
Tr YTD	-1.32
Tr1m	10.04%
Tr1w	-5.58%
Tr3m	-10.78%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	3
Analyst Count Top	1
Analyst Price Target Top	$19
Analyst Ratings	Strong Buy
Analyst Ratings Top	Buy
Earnings EPS Estimate	$-0.2
Operating Income	$-38.4M
Price target	$15
Price Target Change	$101
Price Target Change Top	$155

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	45,485,188%
Float Percent	73.96%
Shares Insiders	18.37%
Shares Institutions	25.08%
Shares Out	61,503,180
Shares Qo Q	38.96%
Shares Yo Y	17.76%
Short Float	5.65%
Short Ratio	12.47
Short Shares	4.18

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-37.9M
Average Volume	184,247.3x
Bv Per Share	1.01
CAPEX	$-588,947
Ch1m	10.04
Ch1w	-5.58
Ch1y	96.83
Ch3m	-10.78
Ch3y	71.26
Ch6m	36.7
Change	-0.27%
Change From Open	-0.4
Close	7.47
Days Gap	0.13
Depreciation Amortization	164,404
Dollar Volume	704,568.9
Earnings Date	2026-05-22
Earnings Time	amc
EBIT	$-38.4M
EBITDA	$-38.3M
EPS	$-1.03
F Score	2
FCF	$-29.1M
FCF EV Yield	-7.09x
FCF Per Share	$-0.47
Financing CF	76,058,540
Fiscal Year End	December
Founded	2,011
Income Tax	$19,091
Investing CF	-588,947
Is Primary Listing	0
Is Spac	No
Last Earnings Date	2026-03-12
Last Report Date	2025-12-31
Last Split Type	Never
Ma150	7.13
Ma150ch	4.55%
Ma20	7.32
Ma20ch	1.82%
Net CF	47,462,188
Next Earnings Date	2026-05-22
Open	7.48
Optionable	No
Position In Range	57.14
Post Close	7.45
Postmarket Change Percent	10.07
Postmarket Price	$8.2
Ppne	987,126
Price Date	2026-05-08
Ptbv Ratio	8.86
Relative Volume	0.51x
Share Based Comp	8,756,107
Tr6m	36.7%
Volume	94,573

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does EPRX pay a dividend?

Capital-return profile for this ticker.

Performance

EPRX stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns EPRX?

Insider, institutional, and short-interest positioning.

Institutional ownership

+25.1%

Float: +74.0% of shares outstanding

Insider ownership

+18.4%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

EPRX momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

52.0

Neutral momentum band

Price vs 200-day MA

+11.0%

50/200-day relationship not available

Beta (5Y)

1.42

More volatile than the market

Sharpe ratio

1.35

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About EPRX

Hub-level FAQ points readers to the deeper analysis pages.

What is the current EPRX stock rating?

Eupraxia Pharmaceuticals Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full EPRX analysis?

The full report lives at /stocks/EPRX/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for EPRX?

The latest report frames EPRX around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the EPRX page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.